Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Uncontrolled essential hypertension defined by office SBP/DBP \> 140/90 or \> 130/80 mmHg for compelling indications (diabetes mellitus, chronic kidney disease, known CAD or CAD equivalent or 10-year Framingham risk score \> 10%)
Previously untreated, or previously treated with a single antihypertensive therapy at usual dose during the last 4 weeks
You may not be if
Female who are pregnant or breast feeding
Office DBP\> 110mmHg or office SBP \>180mmHg
Hypersensitivity to ramipril, felodipine or to any of the excipients
Bilateral stenosis of the renal arteries, or unilateral stenosis in the single kidney
History of intolerance to any ACE inhibitor
History of significant renal diseases including: serum creatinine \>3.0 mg/dl, or creatinine clearance \<30 ml/min
History of hereditary and/or idiopathic angioedema; or angioedema associated with previous ACEI
Significant cardiovascular diseases, multiple drug allergies, bronchospastic disease or other malignancies requiring current medication
Hepatic disease as indicated by any of the following: Serum Glutamooxaloacetate Transferase (SGOT) or Serum Glutamopyruvate Transferase (SGPT)\>3 x upper limit of normal, or serum bilirubin \> 2 x upper limit of normal
Any other condition or therapy that, in the investigator's opinion, or as indicated in the product(s) label may pose a risk to the patient or interfere with the study objective.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | China Medical University Hospital (CMUH) Triapin Listing
